PMID- 35116288
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 10
IP  - 10
DP  - 2021 Oct
TI  - The efficacy and safety of oncolytic viruses in the treatment of intermediate to 
      advanced solid tumors: a systematic review and meta-analysis.
PG  - 4290-4302
LID - 10.21037/tcr-21-905 [doi]
AB  - BACKGROUND: Cancer treatment remains one of the most formidable challenges 
      worldwide. Some novel treatment strategies, including molecularly targeted 
      therapy, gene therapy, and cellular immunotherapy, have also been investigated to 
      improve therapeutic effects for cancer patients and have demonstrated unexpected 
      positive effects. This systematic review and meta-analysis evaluated the efficacy 
      and safety of oncolytic virus (OV) monotherapy or combination therapy for 
      intermediate to advanced solid tumors. METHODS: We retrieved articles from 
      PubMed, Embase, Web of Science, CNKI, Wanfang and VIP. The quality of the 
      included studies was assessed by Review Manager Software version 5.3. STATA 
      software was used to perform meta-analyses of efficacy, overall survival (OS) and 
      adverse reactions. RESULTS: A total of 22 studies involving 3,996 patients were 
      included in this analysis, including 13 H101 studies, 5 T-VEC studies, 2 Pexa-Vec 
      studies, 1 HF10 study and 1 Reolysin study. Regarding oncolytic adenovirus H101, 
      meta-analysis showed that patients treated with H101 monotherapy or H101 combined 
      with chemotherapy had a significantly higher objective response rate (ORR) than 
      those treated with chemotherapy. Patients in the H101 and T-VEC groups had 
      significantly longer effect size (ES) than the control group patients. The odds 
      ratio (OR) and ES of patients with hepatocellular carcinoma, lung cancer and 
      melanoma treated with OV were analyzed. For the safety profile, the total 
      incidence of adverse reactions was similar in both groups. In terms of the other 
      OVs, according to a systematic review, we found that after Reolysin treatment, 
      the ORR was 26.9% in patients with head and neck cancer. The phase I study of 
      HF10 exhibited some therapeutic potential. The adverse events (AEs) associated 
      with the other OVs mainly included fever, nausea and vomiting, leukopenia, and 
      hypotension. DISCUSSION: OVs are effective and well tolerated for the treatment 
      of intermediate to advanced solid cancer and represent a promising therapeutic 
      approach for solid cancers.
CI  - 2021 Translational Cancer Research. All rights reserved.
FAU - Gao, Peng
AU  - Gao P
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Ding, Guanxiong
AU  - Ding G
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Wang, Lujia
AU  - Wang L
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8799180
OTO - NOTNLM
OT  - Oncolytic virus (OV)
OT  - efficacy
OT  - intermediate to advanced solid tumor
OT  - meta-analysis
OT  - safety
OT  - systematic review
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at https://dx.doi.org/10.21037/tcr-21-905). The authors have no 
      conflicts of interest to declare.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/10/01
CRDT- 2022/02/04 05:48
PHST- 2021/05/25 00:00 [received]
PHST- 2021/08/04 00:00 [accepted]
PHST- 2022/02/04 05:48 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/10/01 00:00 [pmc-release]
AID - tcr-10-10-4290 [pii]
AID - 10.21037/tcr-21-905 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2021 Oct;10(10):4290-4302. doi: 10.21037/tcr-21-905.